Given the LOH frequencies detected in our studied cohorts, and the response of the different NAT2 slow acetylator variants to APA, we estimate that each year at least 79.000 worldwide CRC patients could benefit from LOH-based targeting. This evidence concerns the gene NAT2 and colorectal carcinoma.